doi:10.1016/j.ejcsup.2008.06.025S. BarniM. CabidduF. PetrelliElsevier LtdEJC SupplementsS.Barni, M.Cabiddu, F.Petrelli. (2008) Chemo-hormonal therapy for metastatic breast cancer patients: Treatment strategy. European Journal of Cancer Supplements 6 , 13-20 /...
"This is the key step giving cancer cells a foot in the door at a secondary site," said Tsonwin Hai, professor of biological chemistry and pharmacology at The Ohio State University and senior author of the study. "The whole point of our pre-treatment model is to ask the question: Does ...
The women all had stage I or II, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. The patients were also analyzed by nodal status. For node-negative patients, who also included those with micrometastases, the estimated decline in chemotherapy use was f...
Carol Kwok, who led the study, said that pre-surgery chemotherapy may bring "new hopes" for breast cancer patients as a higher pathological complete response (PCR) rate was observed in some aggressive tumor types such as the HER2-positive and the triple-negative breast cancers. "Pathological co...
vascular endothelial cell (VEC)- and tumour cell-targeting factor VII-targeted Sn(IV) chlorin e6 photodynamic therapy (fVII-tPDT) by targeting a receptor tissue factor (TF) as an alternative treatment for chemoresistant breast cancer using a multidrug resistant (MDR) breast cancer line MCF-7/...
f mRNA levels of pro-survival and pro-apoptotic genes in CSCs after treatment with 30 μg/ml of isotype IgG control or mAb17 for 48 h (n = 3). g Apoptotic cells detected by TUNEL assay in CSCs treated with 20 nM of DTX, 30 μg/ml mAb17, or both for 24 h. ...
Breast Cancer Awareness The outlook for women with breast cancer is improving constantly. Due to increased awareness, opportunities for early detection, and treatment advances, survival rates continue to climb. In the U.S., October is Breast Cancer Awareness Month, and the campaign is designed to...
The first results from RxPONDER provide insight – and controversy – regarding the need for chemotherapy by women with node-positive, low-risk HR+, HER2- breast cancer.
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemo- therapy. Breast Cancer Res Treat... S Glück,FD Snoo,J Peeters,... - 《Breast Cancer Research & Treatment》 被引量: 93发表: 2013年 ...
byEuropean Society for Medical Oncology Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated...